These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A. Korth-Bradley J, Rupon J, Plotka A, Charnigo R, Rendo P. Clin Transl Sci; 2018 May; 11(3):283-288. PubMed ID: 29575770 [Abstract] [Full Text] [Related]
4. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A. Liu H, Wu R, Hu P, Sun F, Xu L, Liang Y, Nepal S, Qu PR, Huard F, Korth-Bradley JM. Clin Ther; 2017 Jul; 39(7):1313-1319. PubMed ID: 28601434 [Abstract] [Full Text] [Related]
5. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis. Chowdary P, Fischer K, Collins PW, Cotterill A, Konkle BA, Blanchette V, Pipe SW, Berntorp E, Wolfsegger M, Engl W, Spotts G. Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844 [Abstract] [Full Text] [Related]
6. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A. Jiménez-Yuste V, Lejniece S, Klamroth R, Suzuki T, Santagostino E, Karim FA, Saugstrup T, Møss J. J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795 [Abstract] [Full Text] [Related]
7. Population pharmacokinetics of recombinant factor VIII Fc fusion protein. Nestorov I, Neelakantan S, Ludden TM, Li S, Jiang H, Rogge M. Clin Pharmacol Drug Dev; 2015 Mar; 4(3):163-74. PubMed ID: 27140796 [Abstract] [Full Text] [Related]
9. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T. Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838 [Abstract] [Full Text] [Related]
13. Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates. Lunghi B, Bernardi F, Martinelli N, Frusconi S, Branchini A, Linari S, Marchetti G, Castaman G, Morfini M. J Thromb Haemost; 2019 Aug; 17(8):1288-1296. PubMed ID: 31055871 [Abstract] [Full Text] [Related]
14. von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. van Moort I, Bukkems LH, Heijdra JM, Schutgens REG, Laros-van Gorkom BAP, Nieuwenhuizen L, van der Meer FJM, Fijnvandraat K, Ypma P, de Maat MPM, Leebeek FWG, Meijer K, Eikenboom J, Mathôt RAA, Cnossen MH, OPTI-CLOT Study Group. Thromb Haemost; 2020 Jul; 120(7):1056-1065. PubMed ID: 32480417 [Abstract] [Full Text] [Related]
17. Half-life extended factor VIII for the treatment of hemophilia A. Tiede A. J Thromb Haemost; 2015 Jun; 13 Suppl 1():S176-9. PubMed ID: 26149020 [Abstract] [Full Text] [Related]